Replies to post #24133 on RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, Unless the authorized share limit is increased again (current limit is 105 mil shares), there are only ~38 mil shares available for issuance in a financing (current fully diluted share count is ~67 mil). And that 38 mil share figure has to include any warrants that are part of the deal. This will limit the amount of money that can be raised to approx $5 mil, with a deal looking something like this --

a) 25 mil shares issued at .20 cents (raises $5 mil), plus 13 mil warrants.


Or, if the number of warrants equals the number of shares, then the deal would look something like this -

b) 19 mil shares issued at .20 cents (raises $3.8 mil), plus 19 mil warrants.


So using all the 38 mil available shares, the most we could raise is approx $5 mil, if the deal goes through at .20 cents/share. At .25 cents we could raise approx $6.25 mil, less the usual transaction fees. Of course it remains to be seen if there will be an additional convertible element attached to the deal, toxic (floorless) or otherwise.

[iggs]

Amazing. You guys are still talking and exchanging theories about the "big deal." 1) We are at .20.+ 2) No news from the Co. and 3) Approx. 1 mo. to 1 1/2 months worth of cash left.

This is insanity. You guys are just oblivious. What a misrepresentation of facts. Goes to show you what the human mind will fabricate to avoid the painful truth. I feel better though because Neuro worked into his post that Darryle Schoepp was an NI subscriber. Does that give us comfort at .29?

Blind...you guys are blind!

Iggs

[RufusT]

All these deal making scenarios remind me of the "ultimate game," a stable of experimental economics. The rules are an experimenter pairs two people and hands one of them 10 bucks. That person (the proposer) decides how the money is divided. The second person (the responder) can accept the offer, which allows both players to pocket their shares, or reject the offer, in which case both players walk away empty handed. This experiment has been repeated all over the world from Japan to Indonesia, from the US to Russia and the result is always the same. Instead of swallowing their pride and pocketing a small profit, responders typically rejected any offer they perceived as unfair. Furthermore, proposers anticipated this angry rejection and typically tendered an offer of around five dollars.
That's just about word for word from a book called, "How We Decide" by a neuroscientist named Jonah Lehrer and I think it accurately describes the Cortex deal making scenarios. The only difference is that in the Cortex case Cortex isn't empty handed as in the "ultimate game." It has something that companies on the other side of the deal desperately need. A decent drug candidate.